

1 **MCCAULLEY LAW GROUP LLC**
2 JOSHUA V. VAN HOVEN, (CSB No. 261815)
3 E-Mail: josh@mccauleylawgroup.com
3001 Bishop Dr., Suite 300
3 San Ramon, California 94583
4 Telephone: 925.302.5941

4 RICHARD T. MCCAULLEY (*pro hac vice*)
5 E-Mail: richard@mccauleylawgroup.com
180 N. Wabash Avenue, Suite 601
6 Chicago, Illinois 60601
7 Telephone: 312.330.8105

7 *Attorneys for Plaintiff and Counter-Defendant,*
8 SURGICAL INSTRUMENT SERVICE COMPANY, INC.

9 **UNITED STATES DISTRICT COURT**

10 **NORTHERN DISTRICT OF CALIFORNIA**

11 SURGICAL INSTRUMENT SERVICE
12 COMPANY, INC.

13 *Plaintiff/Counter-Defendant,*

14 v.
15 INTUITIVE SURGICAL, INC.,

16 *Defendant/Counterclaimant.*

Case No. 3:21-cv-03496-VC

Honorable Vince Chhabria

17 **PLAINTIFF SURGICAL
18 INSTRUMENT SERVICE COMPANY,
19 INC.'S MOTION FOR PARTIAL
20 SUMMARY JUDGMENT AND BRIEF
21 IN SUPPORT**

22 Hearing: June 8, 2023

23 Time: 10 AM PT

24 Courtroom: Courtroom 5, 17th Floor

25 Judge: The Honorable Vince Chhabria

26 Complaint Filed: May 10, 2021

27

28

NOTICE OF MOTION AND MOTION

TO ALL PARTIES AND THEIR RESPECTIVE COUNSEL OF RECORD:

PLEASE TAKE NOTICE that on June 8, 2023, at 10:00 a.m., or as soon thereafter as the matter may be heard, in the courtroom of the Honorable Vince Chhabria, United States District Judge for the Northern District of California, located at 450 Golden Gate Avenue, San Francisco, CA 94102, Plaintiff Surgical Instrument Service Company, Inc. will move the Court to grant partial summary judgment in its favor as on Defendant Intuitive Surgical, Inc.'s Affirmative Defense and Counts 1-4 of its Counterclaims.

TABLE OF CONTENTS

I. INTRODUCTION	1
II. FACTS	2
A. Intuitive’s Business Model And Self-Destruct Use Counter	2
B. SIS Sells EndoWrist Repair Services To Major Hospitals Systems And Group Purchasing Organizations, Potentially Saving Hospitals And Patients Hundreds Of Millions Annually	4
C. Intuitive Shuts Down The EndoWrist Repair Business With Threats To Shut Down Hospitals’ Surgical Robot Programs	6
D. Intuitive Attempts To Enlist FDA And Makes False Statements To Hospitals	7
E. Intuitive’s FDA-Related Claims And Defenses Are Based On SIS And Its Technology Partner Purportedly Being “Remanufacturers” That Are Required To Obtain 510(k) Clearance	8
III. STATUTORY AND REGULATORY BACKGROUND	9
A. Statutes Providing For FDA Regulation Of Medical Device And Instrument Manufacturers	9
B. Statutes Providing For Post-Distribution FDA Regulation Of Medical Devices And Instruments	10
C. OEMs Have Tried And Failed To Pass Statutes To Require 510(k) Clearance For Servicing Of Multi-Use Devices And Instruments Such As EndoWrists	11
D. FDA Has Not Issued Final Guidance On What Servicing Activities Constitute Remanufacturing That Requires 510(k) Clearance	13
E. FDA Has Declined To Decide Whether Extending The Intended Use Life Of Multi-Use Devices And Instruments Requires 510(k) Clearance	17
IV. STANDARD OF REVIEW	19
V. ARGUMENT - INTUITIVE’S FDA-RELATED DEFENSES AND COUNTERCLAIMS SHOULD BE DISMISSED	19
VI. CONCLUSION	23

TABLE OF AUTHORITIES

Cases

3	<i>Allergan USA Inc. v. Imprimis Pharm., Inc.</i> CV 17-1551-DOC, 2017 WL 10526121 (C.D. Cal. Nov. 14, 2017)	21
4	<i>Amarin Pharma, Inc. v. Int'l Trade Comm'n</i> 923 F.3d 959 (Fed. Cir. 2019)	20
5	<i>Anderson v. Liberty Lobby, Inc.</i> 477 U.S. 242 (1986)	19
6	<i>Azurity Pharm. v. Edge Pharma, LLC</i> 45 F.4th 479 (1st Cir. 2022)	20
7	<i>Belcher Pharm., LLC v. Hospira, Inc.</i> 1 F.4th 1374 (11 th Cir. 2021)	21
8	<i>Celotex Corp. v. Catrett</i> 477 U.S. 317 (1986)	19
9	<i>First Ascent Ventures Inc. v. DLC Dermacare LLC</i> 312 Fed.Appx. 60 (9th Cir. 2009)	22
10	<i>JHP Pharms., LLC v. Hospira, Inc.</i> 52 F. Supp. 3d 992	21
11	<i>LL B Sheet I, LLC v. Loskutoff</i> 362 F. Supp. 3d 804 (N.D. Cal. 2019)	22
12	<i>Pejepscot Indus. Park, Inc. v. Me. Cen. R.R. Co.</i> 215 F.3d 195 (1st Cir. 2000)	20
13	<i>Precision Instrument Mfg. Co. v. Auto. Maint. Mach. Co.</i> 324 U.S. 806 (1945)	22
14	<i>Rebotix Repair LLC v. Intuitive Surgical, Inc.</i> 8:20-cv-2274-VMC-TGW, 2022 WL 3272538 (M.D. Fla. Aug. 10, 2022)	21
15	<i>Scott v. Harris</i> 550 U.S. 372 (2007)	19
16	<i>Wheeler v. Am. Family Home Ins. Co.</i> 20-cv-01502-JSW, 2022 WL 4624863 (N.D. Cal. Sep. 30, 2022)	22
17	<i>World Nutrition Inc. v. Advanced Enzymes U.S.</i> CV-19-00265-PHX-GMS, 2021 WL 632684 (D. Ariz. Feb. 18, 2021)	20

Other Authorities

19	1906 Pure Food and Drugs Act. 34 Stat. 768.....	9
20	1990's Safe Medical Devices Act. 104 Stat. 4511	10
21	2002 Medical Device User Fee and Modernization Act. 116 Stat. 1588	11
22	2017 Food and Drug Administration Reauthorization Act. H.R. 2430.....	12
23	21 U.S.C. § 321.....	12
24	21 U.S.C. § 351.....	7
25	21 U.S.C. § 360.....	10, 13
26	61 Fed. Reg. 52610.....	14
27	62 Fed. Reg. 67011	14
28	81 Fed. Reg. 11477	14
29	81 Fed. Reg. 46694	14
30	Clarifying Remanufacturing to Protect Patient Safety Act of 2022. 117 H.R. 7253	13
31	Fed. R. Civ. P. 56(a)	19
32	Food and Drug Administration Reauthorization Act of 2017	15, 16
33	Lanham Act	passim
34	The 1938 Federal Food, Drug and Cosmetic Act. 52 Stat. 1040	passim
35	The Medical Device Amendments 90 Stat. 539.....	9

I. INTRODUCTION

2 Plaintiff, SURGICAL INSTRUMENT SERVICE COMPANY ("SIS"), respectfully
3 submits that the Court should enter partial summary judgment against Defendant,
4 INTUITIVE SURGICAL, INC. ("Intuitive") as to all of Intuitive's FDA-related
5 counterclaims and defenses. All of those claims and defenses are predicated on Intuitive's
6 bare allegation – unsupported by FDA guidance or an official, final determination -- that SIS
7 and its technology partners are "remanufacturers" and thus, are required to obtain FDA
8 regulatory clearance for their EndoWrist servicing business. SIS and its technology partners'
9 EndoWrist surgical instrument servicing includes, *inter alia*, extending the intended use life
10 of this multi-use device. That extension is includes resetting Intuitive's built-in-self-destruct
11 usage counter, thus allowing customers to avoid having to throw away EndoWrist instruments
12 after only 10 uses.

13 Intuitive's FDA-related claims and defenses are subject to dismissal as a matter of law
14 because the FDA has not issued final guidance on when or what servicing activities constitute
15 "remanufacturing" of a medical device. Historically, FDA has never asserted its authority in
16 an attempt to regulate companies that repair or service multi-use medical devices such as
17 EndoWrists. Indeed, FDA acknowledges the long-standing and continuing lack of clarity in
18 the distinction between "servicing" and "remanufacturing" for purposes of regulating medical
19 devices. Additionally, Congress has considered but not yet passed legislation necessary to
20 give FDA express statutory authority to regulate medical device servicing.

Relevant to the issues in the present action, FDA has declined to render an official, final determination as to whether service activity extending the intended use life of multi-use medical devices and instruments requires 510(k) clearance. Until Congress enacts legislation or the FDA issues binding guidance, service providers such as SIS and its technology partners are under no legal obligation to obtain FDA regulatory clearance through a 510(k) pre-market notification submission to conduct their business. Consequently, in order to proceed and resolve Intuitive's FDA-related defenses and counterclaims, the Court would be required to create regulatory policy on a question of first impression and make a determination that the

1 FDA has not made. Put another way, in order to find that SIS has made any false or misleading
 2 statements related to whether 510(k) clearance is required for its activites, or that not
 3 obtaining 510(k) clearance raises a defense of unclean hands, the Court would be required to
 4 *create* FDA guidance and preemptively make decisions based on that newly created guidance,
 5 where FDA has explicitly declined to do so.

6 II. FACTS

7 A. Intuitive's Business Model And Self-Destruct Use Counter

8 Intuitive da Vinci “systems consist of a surgeon console or consoles, a patient-side cart,
 9 and a high-performance vision system and use proprietary instruments and accessories.” JVH
 10 Decl., Ex. 1 at 90. “The patient-side cart holds electromechanical arms that manipulate the
 11 instruments inside the patient.” *Id.* at 7. “The da Vinci Surgical System generally sells for
 12 between \$0.5 million and \$2.5 million, depending upon the model, configuration, and
 13 geography, and represents a significant capital equipment investment for [Intuitive] customers
 14 when purchased.” *Id.* at 61. Intuitive’s “[r]ecurring revenue consists of instruments and
 15 accessories revenue, service revenue, and operating lease revenue.” *Id.* at 62. “Instruments
 16 and accessories revenue has grown at a faster rate than systems revenue over time[,]”
 17 increas[ing] to \$3.52 billion in 2022.” *Id.* “Most of the various instruments that [Intuitive]
 18 manufacture[s] incorporate EndoWrist technology with wristed joints for natural dexterity
 19 and tips customized for various surgical procedures.” *Id.* at 8.

20 Intuitive developed the core design for its EndoWrist instruments in the 1990’s. JVH
 21 Decl., Ex. 2 at 1 (listing a 1997 filing date for a core EndoWrist patent); JVH Decl., Ex. 3 at
 22 30:9-31:12 (acknowledging that Intuitive’s Ken Salisbury – [REDACTED] –
 23 – did so [REDACTED]). For almost all EndoWrists – from their original 1990s design to
 24 the present day¹ – a robot arm with four rotating motors interfaces with and turns four
 25 corresponding “discs” of an attached EndoWrist, allowing surgeons to remotely control the
 26 motion of the “distal” (or working) end of the instrument about multiple degrees of freedom

27
 28 ¹ Almost all patents on EndoWrist instruments have long since expired. *See* JVH Decl.
 Ex. 4 at 2 (listing, in Intuitive’s online “Patent Notice,” only two patents for S, Si, and Xi
 EndoWrists that were filed after 2002).

known as of yaw, pitch, roll, and grip. JVH Decl., Ex. 5 at 21:10-25, 40:2-41:10, 49:21-52:20 (Intuitive's Director of Instrument Design Engineering, discussing operational principles and similarities between Si and Xi EndoWrists). This provides multiple advantages over traditional “minimally invasive” surgeries, such as movements that are unavailable with surgeon-held laparoscopic instruments and improved ergonomics over laparoscopic procedures. The general operating principles of the EndoWrist instruments have not changed significantly from the launch of S EndoWrists in 2005 through the present day, and utilize similar discs, pulleys, cables, and rods that receive and translate motion from the motors of the robot arm to control the distal end of the EndoWrist. JVH Decl., Ex. 5 at 17:10-20:19, 49:21-52:20. There are not – and there have never been – electronics of the EndoWrist that “[REDACTED]” to the EndoWrist mechanical components. JVH Decl., Ex. 7 at 108:18-109:22

13 While some initial EndoWrists may be supplied with a da Vinci system, most instruments
14 are purchased separately over the da Vinci system's multi-year useful life. JVH Decl., Ex. 8
15 at 90:15-91:10. The install base of da Vinci systems has steadily grown, such that almost all
16 U.S. hospitals, including most smaller and rural hospitals, find it necessary to have at least
17 one da Vinci system. JVH Decl., Ex. 6 at ¶ 37; JVH Decl., Ex. 9 at ¶ 24. Over 99% of robotic
18 surgical systems used in minimally invasive surgery in the U.S. are Intuitive da Vinci
19 Systems. *Id.* at ¶ 83-85. Once a da Vinci system is purchased, there are no alternative
20 suppliers of new EndoWrist instruments. *Id.* at ¶ 113.

21 Intuitive controls the frequency of EndoWrist instrument replacement via a built-in self-
22 destruct mechanism it calls a “use counter.” JVH Decl., Ex. 10 at ¶¶ 93. A simple memory
23 chip within the EndoWrist instruments decrements every time the EndoWrist instrument is
24 used in surgery, without regard to the actual time or rigor of usage of the EndoWrist in the
25 surgery. *Id.* at ¶¶ 103-107. When the use count (until recently, 10 uses in most instruments)
26 reaches zero, the da Vinci system will no longer recognize the EndoWrist instrument, which
27 must then be thrown away. *Id.* at ¶ 105. Intuitive’s use count values were set by its marketing
28 department, and while Intuitive claims to have performed testing to validate those use limits,

1 for the vast majority of EndoWrist instruments, Intuitive stopped testing once it satisfied its
 2 marketing-determined use limits, despite none of the tested instruments experiencing any
 3 failures. *Id.* at ¶¶ 118-120; Jvh Decl., Ex. 11 at 53:4-57:15, 61:3-66:9; Jvh Decl., Ex. 12 at
 4 51, 55, 56, 60.

5 As Intuitive's surgeon expert admits, use limits are virtually non-existent for other multi-
 6 use surgical instruments, and Intuitive is the only company he is aware of to impose a self-
 7 destruct mechanism on an multi-use instrument. Jvh Decl., Ex. 13 at 40:11-42:11. Where
 8 the use counter's self-destruct methodology has been extremely successful is in driving the
 9 vast majority of Intuitive's profits. Not only is the mechanical operation of EndoWrist
 10 instruments largely unchanged from the initial 1990s design, but the cost of producing
 11 EndoWrist instruments is in the low [REDACTED]. Jvh Decl., Ex. 14 at 52:6-53:9; Jvh
 12 Decl., Ex. 15 at 15-17. Nonetheless, Intuitive sells (mostly replacement) EndoWrists for
 13 thousands of dollars each, and they now account for the majority of Intuitive's billions of
 14 annual revenue and profits. Jvh Decl., Ex. 16 at 11; Jvh Decl., Ex. 1 at 62.

15 B. SIS Sells EndoWrist Repair Services To Major Hospitals Systems And Group
Purchasing Organizations, Potentially Saving Hospitals And Patients Hundreds Of
Millions Annually

17 By early 2019, medical technology companies such as Rebotix Repair and Restore
 18 Robotix had made significant sales of repaired S/Si EndoWrists to a number of hospitals and
 19 systems in the United States. Jvh Decl., Ex. 8 at 74:19-76:17. This was based on a high-
 20 quality and technologically viable solution including circumventing the S/Si self-destruct and
 21 performing a comprehensive inspection and repair process to ensure that the repaired
 22 instrument would operate in the same manner as an Intuitive-provided device. Jvh Decl., Ex.
 23 10 at ¶¶ 68-91.

24 Enter Surgical Instrument Service Company, Inc. ("SIS"). For over 50 years, SIS has
 25 worked closely with hospitals to provide efficient, cost-effective, and (most importantly) safe
 26 servicing of surgical instruments ranging from stainless instruments to more complex systems

27
 28

1 such as surgical video systems and flexible endoscopes.² JVH Decl., Ex. 17 at 2; JVH Decl.,
 2 Ex. 18 at 11:20-12:1. Although still a family-owned business, SIS has achieved a size and
 3 scale that allow it to compete with publicly-held goliaths such as Agiliti and Steris. JVH Decl.,
 4 Ex. 18 at 9:2-11:14, 13:2-18; JVH Decl., Ex. 19 at 9:9-14. Indeed, SIS is one of “three vendors
 5 on Vizient national contract in the instrument repair space.” JVH Decl., Ex. 20 at 87:7-24.
 6 Vizient, in turn, is the country’s largest group purchasing organization (GPO) representing
 7 thousands of hospitals and health care facilities. JVH Decl., Ex. 19 at 52:25-53:8; JVH Decl.,
 8 Ex. 20 at 87:2-6.

9 SIS became aware of the Rebotix EndoWrist repair procedure in spring of 2019, and over
 10 the ensuing months, worked with Rebotix to understand the process and potentially bring it
 11 to SIS customers, including multiple visits to SIS and Rebotix facilities. JVH Decl., Ex. 18 at
 12 23:18-27:20; JVH Decl., Ex. 20 at 23:9-24:16, 32:21-33:18. SIS developed marketing
 13 materials with Rebotix that discuss SIS’s position – from 50 years of experience repairing
 14 hospitals’ instruments without FDA interference – that FDA approval is not required for repair
 15 of hospital-owned EndoWrist instruments: “The da Vinci® EndoWrist® is a “multi-use”
 16 medical device. Multi-use devices, such as endoscopic instruments, have always been eligible
 17 for repair.” JVH Decl., Ex. 21 at 6 (SIS095124). As explained by SIS at the time, “The FDA
 18 does not regulate, nor certify, repairs. The FDA regulates third party reprocessing companies
 19 and single-use devices only.” *Id.* at 2 (SIS095120).

20 SIS began offering the S/Si EndoWrist and repair process to its customer base in fall of
 21 2019, and quickly gained a foothold with major hospital systems in this district as well as
 22 numerous other major systems in other regions of the country. JVH Decl., Ex. 20 at 109:9-
 23 110:13-24, 116:1-9; JVH Decl., Ex. 8 at 88:7-19. SIS signed an agreement with Vizient
 24 specific to EndoWrist repairs, making SIS the only Vizient-approved supplier of EndoWrist
 25

26 ² EndoWrists fall somewhere in the middle relative to complexity of devices that SIS
 27 typically repairs. For example, the tools on the distal ends of EndoWrists are virtually
 28 identical to the tools of conventional forceps, scalpels, scissors and the like. The cable and
 pulley systems of EndoWrists share many similarities with flexible endoscopes, but are much
 shorter and do not have to snake through multiple turns. JVH Decl. Ex. 10 at ¶¶ 133-136;
 JVH Decl. Ex. 22 at 174:19-175:3.

1 repairs for Vizient's thousands of healthcare member facilities.³ JVH Decl., Ex. 18 at 77:14-
 2 78:20; JVH Decl., Ex. 19 at 52:5-24; JVH Decl. Based on the substantial cost-savings and
 3 hospitals' frustration with Intuitive's business practices, hospital demand for the EndoWrist
 4 repair service was "monumental." JVH Decl., Ex. 20 44:7-45:22; JVH Decl., Ex. 19 at 50:10-
 5 51:24. Every hospital system that discussed the EndoWrist repair service was interested,
 6 including "Legacy Health system in Portland, Oregon; Providence health system in the West
 7 Coast; Sutter Health; Kaiser Permanente; memorial care; the UC system in California; Banner
 8 Health System; Honor Health; Baylor Scott & White in Texas; the university health systems
 9 across the country, from Michigan to Duke to North Carolina; Mayo Clinic; Cleveland Clinic;
 10 Advocate Aurora; Lahey Health System; Boston Children's Medical Center . . . Piedmont
 11 health system, Grady in Atlanta, Johns Hopkins . . . And then, in addition to that, all the
 12 Vizient conversations we've had, I've presented to all four regions of Vizient, which basically
 13 covers well over 2,000 hospitals in the United States." JVH Decl., Ex. 20 45:2-45:22.

14 There is there no dispute that SIS's activities have never been challenged by FDA in over
 15 50 years in business: "The FDA stayed out of repair. . . [I]t has not been a necessity to deal
 16 with any regulatory issues with re- -- regarding the repair of surgical instrumentation." JVH
 17 Decl., Ex. 23 at 44:18-45:3; JVH Decl., Ex. 20 at 46:3-12.

18 C. Intuitive Shuts Down The EndoWrist Repair Business With Threats To Shut Down
Hospitals' Surgical Robot Programs

20 Concerned with the escalating adoption of EndoWrist repair in late 2019, Intuitive sent
 21 threat letters to virtually every hospital where it discovered use of repaired EndoWrists,
 22 including to SIS's customers. *E.g.*, JVH Decl., Ex. 8 at 79:18-81:15, 88:7-19, 92:17-94:7;
 23 JVH Decl., Ex. 24; JVH Decl., Ex. 25. The threats in those letters were explicit – if the
 24 hospital continued to use repaired S/Si EndoWrists, Intuitive would effectively shut down the
 25 hospital's entire robotic surgery program, including by withholding service for the surgical
 26

27 ³ SIS also presented to the Vizient sales force at Vizient regional meetings, ensuring that
 28 word of the EndoWrist repair service would also be shared by Vizient personnel. JVH Decl.
 Ex. 20 at 44:19-45:22, 88:8:14.

1 robots and voiding the warranty for the da Vinci systems (not just the EndoWrists). JVH Decl.,
2 Ex. 24 at 2-3; JVH Decl., Ex. 25 at 2-3. For example:

3 [REDACTED]
4 [REDACTED]
5 [REDACTED]
6 [REDACTED]
7 E.g., JVH Decl., Ex. 24 at 3; JVH Decl., Ex. 25 at 3. Faced with the shutdown of their robotic
8 surgery programs, all SIS customers (and to SIS's knowledge, all EndoWrist repair
9 customers) stopped using repaired EndoWrists. JVH Decl., Ex. 18 at 39:21-40:5, 41:23-
10 44:19; JVH Decl., Ex. 19 at 55:12-56:7, JVH Decl., Ex. 22 at 39:3-41:4.

11 D. Intuitive Attempts To Enlist FDA And Makes False Statements To Hospitals

12 Intuitive's threat letter to hospitals also contends that ' [REDACTED]

13 [REDACTED]
14 [REDACTED] " E.g., JVH Decl., Ex. 25 at 3. According
15 to Intuitive's hospital threat letter, services such as those provided by SIS require an additional
16 FDA clearance: " [REDACTED]

17 [REDACTED] ." *Id.*

18 Intuitive also brought this campaign directly to FDA in January of 2020, alleging that

19 [REDACTED]
20 [REDACTED] JVH Decl., Ex. 26 at 1.

21 According to Intuitive, " [REDACTED]

22 [REDACTED] ." *Id.* at 2 (emphasis added).

23 According to Intuitive, [REDACTED]
24 [REDACTED]
25 [REDACTED]
26 [REDACTED]

27 [REDACTED] *Id.* at 3

1 As discussed in § III below, Intuitive made these representations to hospitals and to FDA
 2 at a time when FDA had explicitly and publicly stated that it was undecided as to what
 3 activities constitute remanufacturing and are thus potentially subject to FDA regulation such
 4 as 510(k) approval.

5 E. Intuitive's FDA-Related Claims And Defenses Are Based On SIS And Its
 6 Technology Partner Purportedly Being "Remanufacturers" That Are Required To
Obtain 510(k) Clearance

7 Intuitive's only Affirmative Defense alleges in part that "SIS's claims are barred, in whole
 8 or in part, by the doctrine of unclean hands because SIS has acted contrary to applicable FDA
 9 regulations . . ." Dkt. 75 at p. 39 ("First Defense"). Intuitive's unfair competition and false
 10 advertising claim under the Lanham Act (Count 1) and its derivative state law claims (Counts
 11 2-4) similarly rely in part on allegations that "SIS has made numerous false and misleading
 12 statements, including . . . that the 'repair' and/or resulting instruments do not require clearance
 13 by the FDA[.]" *Id.* at ¶ 85 (Count 1), ¶¶ 93, 99, 102 (referring to "conduct detailed above"
 14 in Count 2, "statements detailed above" in Count 3, and "above-detailed deceptive and
 15 fraudulent conduct" in Count 4).

16 To support its allegation that "SIS has acted contrary to FDA regulations[.]" Intuitive
 17 relies on a purported requirement that SIS obtain 510(k) clearance: "SIS further sold a service
 18 to customers that required 510(k) clearance under FDA rules and regulations, despite not
 19 having such clearance." Dkt. 75, Counterclaim ("CC") at ¶ 77. According to Intuitive, "FDA
 20 cleared EndoWrists as limited use or 'reposable' instruments with use limits, and any
 21 modification of EndoWrists by a third party to increase the use limits requires a new 510(k)
 22 clearance." *Id.* at ¶ 4. Intuitive alleges SIS's initial supplier "Rebotix never received 510(k)
 23 clearance from the FDA for its operations or for the marketing and sale of EndoWrists with
 24 overridden use counters [and] [u]pon information and belief, SIS knew that Rebotix never
 25 received 510(k) clearance and was aware of Rebotix's prior communications with the FDA
 26 in which Rebotix failed to obtain any such clearance." *Id.* at ¶ 50.

27 Intuitive further alleges that "[b]ased on the false premise that the [SIS] service is merely
 28 a 'repair' of EndoWrists, SIS . . . misinforms customers that 'repaired' instruments do not

1 require 510(k) premarket clearance by the FDA.” Dkt. 75, CC at ¶ 11. SIS instead purportedly
 2 engages in “unauthorized modification and remanufacturing of Intuitive’s EndoWrist surgical
 3 instruments (‘EndoWrists’)” in a manner that is not “consistent with both EndoWrists’ design
 4 specifications and FDA clearances.” Dkt. 75, CC at ¶ 1. Intuitive thus alleges that SIS
 5 performs “remanufacturing,” not “repair.” *E.g.*, Dkt. 75, CC at ¶¶ 8, 61, 64, 86, 92, 94, 97.

6 III. STATUTORY AND REGULATORY BACKGROUND

7 A. Statutes Providing For FDA Regulation Of Medical Device And Instrument 8 Manufacturers

9 The predecessor agency to the Food and Drug Administration (“FDA”) originated with
 10 the 1906 Pure Food and Drugs Act. 34 Stat. 768, Ch. 3915 (JVH Decl., Ex. 27 at 768). The
 11 1938 Federal Food, Drug and Cosmetic Act (“FD&C Act”) stated that “[n]o person shall
 12 introduce or deliver for introduction into interstate commerce any new drug, unless an
 13 application [filed with the Secretary] is effective with respect to such drug.” 52 Stat. 1040 at
 14 § 505(a) (JVH Decl., Ex. 28 at 1052). As FDA explained in a 2006 article entitled “Medical
 15 Device and Radiological Health Regulations Come of Age,”⁴ from 1938 until the 1976
 16 passage of the “Medical Device Amendments” to the FD&C Act, “devices were subject only
 17 to policing by the FDA” and “[t]here was . . . no requirement for premarket testing, review,
 18 or approval.” JVH Decl., Ex. 29 at 3-4.

19 The Medical Device Amendments set forth requirements for premarket approval of
 20 medical devices, including through amendments such as to Section 510 of the FD&C Act and
 21 new Sections 513-521. *See* 90 Stat. 539 (JVH Decl., Ex. 30 at 539-540, 579-580). Section
 22 510 regarding “REGISTRATION OF **PRODUCERS** OF DRUGS” was “amended by
 23 inserting ‘AND DEVICES’ after ‘DRUGS.’” *Id.* at 579 (emphasis added). Section 510(k)
 24 was added to require “[e]ach person who is required to register under this section [510] and
 25 **who proposes to begin the introduction or delivery for introduction into interstate**
 26 **commerce for commercial distribution of a device**” to comply with certain reporting

27
 28 ⁴ Available at <https://www.fda.gov/files/about%20fda/published/Medical-Device-and-Radiological-Health-Regulations-Come-of-Age.pdf>

1 requirements, including reporting compliance with the requirements of Section 514
 2 (Performance Standards) and Section 515 (Premarket Approval). *Id.* at 580 (emphasis added);
 3 *see also* 21 U.S.C. § 360(k). *Registration*, in turn, is limited to “every person who owns or
 4 operates any establishment in any State engaged in the manufacture, preparation, propagation,
 5 compounding, or processing of a device or devices[.]” 21 U.S.C. § 360(b)(2) (“Section
 6 510(b)(2)"); *see also* 90 Stat. 579 (inserting “device or devices”). The “Definitions” of
 7 Section 510 is clear that, as with the reporting requirements of § 510(k), Section 510's
 8 registration requirements are limited to entities in the original production and distribution
 9 chain of the medical device:

10 [T]he term “manufacture, preparation, propagation, compounding, or
 11 processing” shall include repackaging or otherwise changing the container,
 12 wrapper, or labeling of any drug package or device package **in furtherance of**
the distribution of the drug or device from the original place of
manufacture to the person who makes final delivery or sale to the ultimate
consumer or user[.]
 13

14 21 U.S.C. § 360(a)(1) (“Section 510(a)(1)”) (emphasis added); *see also* 90 Stat. 579 (inserting
 15 “device package,” “device,” and “user”).

16 B. Statutes Providing For Post-Distribution FDA Regulation Of Medical Devices And
Instruments
 17

18 In two instances, Congress has expanded FDA's authority over medical devices to cover
 19 post-distribution activities, including by requiring reporting of medical device failures by
 20 hospitals and by authorizing regulation of reprocessors of single-use devices. Section 519 of
 21 the original Medical Device Amendments included recordkeeping and reporting requirements
 22 that applied to “[e]very person who is a manufacturer, importer, or distributor of a device
 23 intended for human use[.]” 90 Stat. (JVH Decl., Ex. 30) at 564. 1990's Safe Medical Devices
 24 Act (“SMDA”) expanded Section 519's reporting requirements to “[w]henever a device user
 25 facility receives or otherwise becomes aware of information that reasonably suggests that
 26 there is a probability that a device has caused or contributed to the death of a patient of the
 27 facility” or “caused or contributed to the serious illness of, or serious injury to, a patient of
 28 the facility.” 104 Stat. (JVH Decl., Ex. 31) 4511.

1 The 2002 Medical Device User Fee and Modernization Act (“MDUFMA”) “expand[ed]
 2 FDA regulation of the medical device reprocessing industry” (Congressional Record 107
 3 (2002) – JVH Decl., Ex. 32 at S10754 (C. Dodd)) by “regulating the reprocessing of single
 4 use devices” *Id* at S10755 (H. Reid). The MDUFMA accomplished this by imposing, under
 5 the heading of “SINGLE-USE MEDICAL DEVICES,” certain “LABELING” and
 6 “PREMARKET NOTIFICATION” obligations on entities involved with “reprocessed single-
 7 use devices.” *See* 116 Stat. (JVH Decl., Ex. 33) at 1616-20. Specific to 510(k) approvals, the
 8 MDUFMA required that “The Secretary shall identify such [reprocessed single-use] devices
 9 or types of [reprocessed single-use] devices for which reports under such subsection [510(k)]
 10 must, in order to ensure that the device is substantially equivalent to a predicate device,
 11 include validation data, the types of which shall be specified by the Secretary, regarding
 12 cleaning and sterilization, and functional performance demonstrating that the single-use
 13 device will remain substantially equivalent to its predicate device after the maximum number
 14 of times the device is reprocessed as intended by the person submitting the premarket
 15 notification.” *Id.* at 1616-17. The definition of “reprocessed” within these sections is limited
 16 to the context of single-use devices and a “single-use device” is limited to “a device that is
 17 intended for one use, or on a single patient during a single procedure.” *Id.* at 1619-20.

18 C. OEMs Have Tried And Failed To Pass Statutes To Require 510(k) Clearance For
 19 Servicing Of Multi-Use Devices And Instruments Such As EndoWrists

20 On April 25, 2017 – following 40 years of failed lobbying efforts by medical device OEMs
 21 to get FDA to require registration, approval, or other regulation of third-party servicers of
 22 medical devices such as SIS – H.R. 2118 was introduced in the House of Representatives.
 23 115 H.R. 2118 (JVH Decl., Ex. 34). The proposed bill would have amended Section 510 of
 24 the FD&C Act to define “servicing” as “include[ing], with respect to a device, refurbishing,
 25 reconditioning, rebuilding, remarketing, repairing, or other servicing of the device by a person
 26 other than the manufacturer of the device.” *Id.* at § (r)(2). The bill also proposed amending
 27 Section 510’s registration requirements to include “any person who owns or operates any
 28 establishment in any State engaged in the servicing of a device or devices, or is otherwise

1 engaged in the servicing of a device or devices” and to make servicers subject to Section
 2 519’s reporting requirements, “by striking ‘manufacturer or importer’ each place it appears
 3 and inserting ‘manufacturer, servicer, or importer[.]’” *Id.* at § 2-(b)(1)(A) and § 2-(r)(1).

4 The bill that became the 2017 Food and Drug Administration Reauthorization Act (“2017
 5 Act”), as introduced on May 16, 2017, did not include any discussion of device servicing. *See*
 6 H.R. 2430 (JVH Decl., Ex. 35). The final bill passed later that year rejected the OEMs’ attempt
 7 impose new 510(k) clearance on servicing. Instead, the 2017 Act required, in Section 710,
 8 that FDA prepare a “REPORT ON SERVICING OF DEVICES.” Public Law 115-52; 131
 9 Stat. 1006 (JVH Decl., Ex. 36) at 1067-68. Section 710 of the 2017 Act required FDA to “post
 10 on the internet website of the Food and Drug Administration a report on the continued quality,
 11 safety, and effectiveness of devices (as defined in section 201(h) of the Federal Food, Drug,
 12 and Cosmetic Act (21 U.S.C. § 321(h))) with respect to servicing (as defined in subsection
 13 (c)).” *Id.* at 1067-68. Subsection (c) of Section 710 of the 2017 Act defined “servicing” to
 14 include “remanufacturing”: “SERVICING DEFINED.—In this section, the term ‘servicing’
 15 includes, with respect to a device, refurbishing, reconditioning, rebuilding, remarketing,
 16 repairing, **remanufacturing**, or other servicing of the device.” *Id.* at 1068.

17 Sections 710(a)(1)-(2) of the 2017 Act required FDA’s report to include findings resulting
 18 from a 2106 proposed FDA rule and from a 2016 public workshop on the proposed rule. *Id.*
 19 at 1068. Section 710(a)(3)-(4) required FDA’s report to include “a description of the statutory
 20 and regulatory authority” over servicing (including remanufacturing) and “whether additional
 21 authority is recommended[.]” *Id.* The 2016 proposed rule, workshops and FDA’s resulting
 22 “FDARA 710 – 3rd Party Servicing Report” report are discussed further in § III(D), *infra*.

23 Unhappy with the results of the 2017 Act, the FDARA 710 report, and FDA’s continued
 24 failure to require 510(k) clearance for servicing, the OEMs took a different tack in the last
 25 year. On March 28, 2022, H.R. 7253 was introduced in Congress “[t]o amend the Federal
 26 Food, Drug, and Cosmetic Act to provide for clarification of requirements for the
 27 remanufacturing of medical devices, and for other purposes.” 117 H.R. 7253 (JVH Decl., Ex.
 28 37) at 1. Titled the “Clarifying Remanufacturing to Protect Patient Safety Act of 2022,” H.R.

1 7253 proposed to change the definition of “manufacturing” in Section 510 of the FD&C Act
 2 to add remanufacturing – thus changing who must register and potentially obtain Section
 3 510(k) clearance – as follows (**new language in bold**):

4 Section 510 of the Federal Food, Drug, and Cosmetic 9 Act (21 U.S.C. 360)
 5 is amended—

6 (1) by subsection (a), by amending paragraph (1) to read as follows:

7 “(1) The term ‘manufacture, preparation, propagation, compounding,
 8 or processing’ shall include **the following**:

9 **“(A) Repackaging or otherwise changing the container, wrapper,
 10 or labeling of any drug package or device package in furtherance of
 11 the distribution of the drug or device from the original place of
 12 manufacture to the person who makes final delivery or sale to the
 13 ultimate consumer or user.**

14 **(B) Remanufacturing of any finished device by engaging in
 15 any act that could significantly change the performance or
 16 safety specifications, or intended use, of the finished device,
 17 including by significantly changing—**

18 **(i) a sterilization method;**

19 **(ii) a reprocessing instruction;**

20 **(iii) a control mechanism, operating principle, or energy
 21 input or output;**

22 **(iv) the anatomical location of use; or**

23 **(v) the design[.]**

24 *Id.* at 2 (emphasis added).⁵ As of the date of this filing, the OEMs have not been successful
 25 in persuading Congress to change the definition of “manufacture” under Section 510 of the
 26 FD&C Act to include “remanufacturing” or to enumerate specific activities that require
 27 510(k) clearance. *See* JVH Decl., Ex. 38.

28 D. FDA Has Not Issued Final Guidance On What Servicing Activities Constitute
 29 Remanufacturing That Requires 510(k) Clearance

30 FDA first proposed a definition for “remanufacturing” in 1996: “Remanufacturer means
 31 any person who processes, conditions, renovates, repackages, restores, or does any other act

32

⁵ The bill also sought to impose new requirements for “Device Remanufacturing Public
 33 Education” and a program for “Enhanced Communications Regarding Remanufacturing” that
 34 allows any third party to “express[] concerns that an entity that is remanufacturing devices –
 35 (A) is not registered under section 510 of the Federal Food, Drug, and Cosmetic Act (21
 36 U.S.C. 360)[.]” 117 H.R. 7253 at §§ (3)-(5) (JVH Decl. Ex. 37 at 3-7).

1 to a finished device that significantly changes the finished device's performance or safety
 2 specifications, or intended use." 61 Fed. Reg. 52610 (JVH Decl., Ex. 39) at 52641, 52656.
 3 As FDA explained in a 1997 Federal Register Notice, "[r]emarketing used devices may
 4 consist of activities that significantly change the finished device's performance or safety
 5 specifications, or intended use . . . [and thus] constitute 'remanufacturing' as defined in the
 6 Quality System regulation (QS)[.]" 62 Fed. Reg. 67011 (JVH Decl., Ex. 40).

7 FDA largely left these issues alone for nearly 20 years,⁶ seeking to revisit them in 2016
 8 after certain "[s]takeholders have expressed concerns" regarding "some third-party entities
 9 who refurbish, recondition, rebuild, remarket, remanufacture, service, and repair medical
 10 devices . . ." 81 Fed. Reg. 11477 (JVH Decl., Ex. 41) at 11478. FDA requested comments
 11 and indicated its intent to hold public meetings regarding proposed definitions and appropriate
 12 regulatory schemes for the following: "Recondition," "Service," "Repair," "Refurbish,"
 13 "Remanufacture," and "Remarket." *Id.* at 11478-79.

14 FDA followed up with notice of a public workshop entitled "Refurbishing,
 15 Reconditioning, Rebuilding, Remarketing, Remanufacturing, and Servicing of Medical
 16 Devices Performed by Third-Party Entities and Original Equipment Manufacturers", which
 17 was scheduled for October 2016. 81 Fed. Reg. 46694 (JVH Decl., Ex. 42). In the summary
 18 discussing the upcoming workshop, FDA stated that one topic would be "**whether these**
 19 **activities should appropriately be regulated by FDA or a non-governmental**
 20 **organization.**" *Id.* (emphasis added). As the Deputy Director for Regulatory Oversight and
 21 Analysis in the Division of Analysis and Program Operations of FDA's Office of Compliance
 22 explained at one of those public meetings (held October 27, 2016):

23 Then the quality system regulation came along. And there was a decision in
 24 '93 to update what was then the CGMPs and we wanted to codify basically

25 ⁶ "Over the past 20 years, the Center for Devices and Radiological Health has sought to
 26 clarify our regulatory requirements and expectations, under part 820 (21 CFR part 820), to
 27 entities servicing, refurbishing, rebuilding, reconditioning, remarketing, and remanufacturing
 28 medical devices." 81 Fed. Reg. (JVH Decl. Ex. 41) at 11478. However, other than some
 specific discussions of x-ray and laser systems, the only clarification that FDA mentioned
 over those 20 years was that "[i]n the Federal Register on December 4, 1998 (63 FR 67076),
 refurbishers and servicers of medical devices were excluded from the requirement to comply
 with the 1997 Quality System Regulation under part 820." *Id.*

1 what the policy was. And so the proposed rule included third-party servicers
 2 and refurbishers as being subject to all of the proposed changes in the new
 3 quality system regulation.

4 Well, there were a lot of comments about this; there was a lot of contentious
 5 discussions about it. And it got to the point where this particular subject could
 6 have derailed the proposed rule from becoming final.

7 * * *

8 So 1997 we actually published what is known as Advance Notice of Public
 9 Rulemaking which is sort of the pre-step of having a proposed rule. And this
 10 is where the refurbisher, reconditioner, servicers, all that verbiage comes from.
 11 . . . At that time no one could agree what the right term was. **And I think we**
 12 **are still at that point where nobody really knows what the best term to**
 13 **use for this particular situation is.**

14 * * *

15 Since 1998 no one has had to register with us, no one has been subject to
 16 inspection except for cause if there is a concern that you are not really
 17 refurbishing but you are actually remanufacturing a device because you are
 18 changing the intended use. **So the industry has not really had any**
 19 **involvement with FDA except our interactions with some of the trade**
 20 **associations since 1998.**

21 So here we are today. So in March we published the request for comment about
 22 this subject. We got 177 comments, more than twice what we got 20 years ago.
 23 And we are here today to talk about what those comments said and some of
 24 the other issues that were raised.

25 FDA Public Meeting, October 27, 2016 (JRH Decl., Ex. 43) at 16-21 (emphasis added).

26 FDA issued its “Report on the Quality, Safety, and Effectiveness of Servicing of Medical
 27 Devices In accordance with Section 710 of the Food and Drug Administration
 28 Reauthorization Act of 2017 (FDARA)” in May of 2018.⁷ JRH Decl., Ex. 44 (the “2018
 29 FDARA Report”). The 2018 FDARA Report acknowledged that “FDA generally has not
 30 enforced FD&C Act requirements with respect to servicing activities . . .”⁸ Ex. 44 at 4. FDA

31 _____
 32 ⁷ FDA Report on the Quality, Safety, and Effectiveness of Servicing of Medical Device,
 33 (published by the FDA in May 2018, and available at
 34 <https://www.fda.gov/media/113431/download>) (hereafter “FDA 2018 Report”).

35 ⁸ This statement applied equally to “remanufacturing.” Compare 2018 FDARA Report
 36 (JRH Decl. Ex. 44) at p.iii n.2 (“[G]iven the definition in section 710(c) of FDARA, **unless**
 37 **otherwise specified in this report** (e.g., when expressly describing the differences in FDA
 38 regulation concerning servicing and remanufacturing), **references to ‘servicing’ throughout**
 39 **this report generally include all of the activities identified in section 710(c)**” (emphasis
 40 added); *with* 131 Stat 1006 (JRH Decl. Ex. 36) at 1068 (Section 710(c) of FDARA, stating
 41 that “[i]n this section, the term ‘servicing’ includes, with respect to a device, refurbishing,
 42 reconditioning, rebuilding, remarketing, repairing, **remanufacturing**, or other servicing of
 43 the device” (emphasis added)).

1 ultimately concluded that it would not impose additional or different regulatory requirements
 2 on the third-party servicers of medical devices:

3 The currently available objective evidence is not sufficient to conclude
 4 whether or not there is a widespread public health concern related to servicing,
 5 including by third party servicers, of medical devices that would justify
 6 imposing additional/different, burdensome regulatory requirements at this
 7 time;

8 Rather, the objective evidence indicates that many OEMs and third party
 9 entities provide high quality, safe, and effective servicing of medical devices;
 10

* * *

10 We believe the currently available objective evidence is not sufficient to
 11 conclude whether or not there is a widespread public health concern related to
 12 servicing of medical devices, including by third party servicers, that would
 13 justify imposing additional/different burdensome regulatory requirements at
 14 this time.

15 2018 FDARA Report at p. i. FDA did, however, decide to “Clarify the Difference Between
 16 Servicing and Remanufacturing”:

17 Because of the apparent confusion we have heard from stakeholders
 18 concerning the difference between servicing and remanufacturing activities,
 19 FDA intends to publish guidance to assist in differentiating these activities to
 20 allow more consistent interpretation and categorization. In turn, this will
 21 clarify regulatory responsibilities for entities performing these activities and
 22 allow FDA to focus its regulatory oversight on those activities that have the
 23 greatest impact on the quality, safety, and effectiveness of medical devices. **In
 24 accordance with good guidance practices, FDA intends to publish the
 25 guidance in draft form and accept public comments before issuing final
 26 guidance.**

27 2018 FDA White Paper at pp. 24-25 (emphasis added).

28 FDA issued a White Paper “For Discussion Purposes Only” to facilitate a 2018 workshop
 29 entitled “Medical Device Servicing and Remanufacturing Activities”⁹ JVH Decl., Ex. 45
 30 (“the 2018 FDA White Paper”). FDA indicated that “[t]his white paper is for discussion
 31 purposes only and does not represent draft or final guidance.” *Id.* at p. 1.

32 Following up on these workshops and the White Paper, in June 2021, FDA issued a “Draft
 33 – Not for Implementation” that “Contains Nonbinding Recommendations” regarding
 34 “Remanufacturing of Medical Devices.” JVH Decl., Ex. 46 (the “2021 Draft

35 ⁹ White Paper: Evaluating Whether Activities are Servicing or Remanufacturing,
 36 published by FDA in December 2018 and available at
 37 <https://www.fda.gov/media/117238/download>.

1 Remanufacturing Guidance”). In the Introduction, FDA acknowledged that the continuing
 2 lack of clarity in the distinction between “servicing” and “remanufacturing” impacts FDA’s
 3 regulatory authority and the regulatory responsibilities of entities performing such activities:

4 [T]here is a lack of clarity regarding the distinction between “servicing” and
 5 “remanufacturing” of a device. Most notably, remanufacturing has
 6 implications for the regulatory responsibilities of entities performing these
 7 activities.

8 *Id.* at p. 1. FDA stated that “[t]his draft guidance document is being distributed for comment
 9 purposes only.” *Id.* at Cover Page. Further, “[t]his draft guidance, **when finalized**, will
 10 represent the current thinking of the Food and Drug Administration (FDA or Agency) on
 11 this topic.” *Id.* (emphasis added). The 2021 Draft Remanufacturing Guidance has not been
 12 finalized as of the date of this filing. *See, e.g.*, <https://www.fda.gov/medical-devices/quality-and-compliance-medical-devices/remanufacturing-and-servicing-medical-devices> (live FDA
 13 website providing links to draft guidance, white papers, and workshops).

14 E. FDA Has Declined To Decide Whether Extending The Intended Use Life Of Multi-
 15 Use Devices And Instruments Requires 510(k) Clearance

16 Relevant to the present action, in the 2018 FDA White Paper, FDA sought comment as to
 17 whether certain example scenarios were “servicing” or “remanufacturing,” explaining that
 18 “[s]takeholders should comment on whether the accompanying text and flowchart adequately
 19 and clearly capture the thought process that would distinguish between servicing and
 20 remanufacturing activities.” 2018 FDA White Paper (JVH Decl., Ex. 45) at p.12. In one of
 21 the scenarios, “[s]ome components/parts/materials have a defined intended use life which
 22 limits the life expectancy of the device . . . [and] [a]ctivities are performed to extend the
 23 device’s intended use life.” *Id.* at pp. 15-16 (emphasis added).

24 FDA’s 2021 Draft Remanufacturing Guidance laid out 15 dense pages of “Definitions,”
 25 “Guiding Principles,” “Relevant Considerations,” and a multi-stage flowchart through which
 26 industry participants could ultimately reach alternatives of “Likely Not Remanufacturing” or
 27 “Likely Remanufacturing.” 2021 Draft Remanufacturing Guidance (JVH Decl., Ex. 46) at pp.
 28 1-15. Perhaps recognizing that these sections of the Draft Guidance provided minimal clarity,

1 FDA's Draft Guidance also provided "Decisions" as to whether certain of the example
2 scenarios were "Remanufacturing" or "Not Remanufacturing." *Id.* at pp. 18-32. Notably, the
3 example scenario from the 2018 White Paper where "[a]ctivities are performed to extend the
4 device's intended use life" was omitted from the 2021 Draft Remanufacturing Guidance
5 without a "Decision." *Compare id.* at pp. 18-32; with Jvh Decl., Ex. 45 at pp. 15-16.

6 Less than one month after Intuitive wrote FDA asking it to investigate the supplier of
7 SIS's initial technology solution and repair process (Rebotix), FDA employees reached out
8 to Rebotix stating that "we believe that a 510(k) is needed to continue your operation."
9 Compare Jvh Decl., Ex. 26 at 1-2, 6 (on January 29, 2020, writing to FDA stating that
10 Rebotix is " [REDACTED]" and
11 " [REDACTED]");
12 with Jvh Decl., Ex. 47 at 2 (on February 28, 2020, a "Biomedical Engineer" from FDA
13 following up on February 20 and February 28 phone calls, and stating that "we believe that
14 510(k) is needed before you continue your operation").

15 These conversations continued for over a year, but never formally rose above a “Team
16 Lead” who was “[REDACTED].” Jvh Decl., Ex. 48 (correspondence
17 with “Team Lead”); Jvh Decl., Ex. 49 at 99:23-100:3. Faced with continued intransigence
18 from low-level FDA employees, Rebotix asked to formally appeal what these FDA
19 employees had referred to as a “decision.” Jvh Decl., Ex. 48; Jvh Decl., Ex. 49 at 98:18-
20 100:3. [REDACTED]
21 [REDACTED]
22 [REDACTED] Jvh Decl., Ex. 49 at 98:18-100:3. According
23 to the FDA “Team Lead”:

24 Informal communications with FDA staff do not represent the formal position
25 of FDA and do not bind or otherwise obligate or commit the agency to the
views expressed. This is why there is nothing for Rebotix to appeal at this
time.

26 JVH Decl Ex 48

IV. STANDARD OF REVIEW

2 Summary Judgment is proper when the record shows “no genuine dispute as to any
3 material fact and the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(a);
4 *Celotex Corp. v. Catrett*, 477 U.S. 317, 322–23 (1986). A factual issue is genuine “if the
5 evidence is such that a reasonable jury could return a verdict for the nonmoving party.”
6 *Anderson v. Liberty Lobby, Inc.*, 477 U.S. 242, 248 (1986). A fact is material if it is necessary
7 to prove or defend against a claim, as determined by the applicable substantive law. *Id.* at
8 255. Although “[t]he evidence of the non-movant is to be believed, and all justifiable
9 inferences are to be drawn in his favor” (*id.* at 255), a court may disregard the non-movant’s
10 version of the facts where it is “blatantly contradicted by the record, so that no reasonable
11 jury could believe it.” *Scott v. Harris*, 550 U.S. 372, 380 (2007).

V. ARGUMENT - INTUITIVE'S FDA-RELATED DEFENSES AND COUNTERCLAIMS SHOULD BE DISMISSED

14 Intuitive’s unfair competition and false advertising claim under the Lanham Act (Count
15 1) and its derivative state law claims (Counts 2-4) allege in part that “SIS has made numerous
16 false and misleading statements, including . . . that the ‘repair’ and/or resulting instruments
17 do not require clearance by the FDA[.]” Dkt. 75 at ¶ 85. However, any SIS statements that
18 it did not require clearance by the FDA cannot be false or misleading where FDA has not
19 enforced regulations against SIS or issued standards on the underlying issue of what activities
20 constitute remanufacturing, and thus require 510(k) clearance.

21 Although the default rule from *POM Wonderful*¹⁰ is that Lanham Act claims can coexist
22 with FDA's enforcement and regulatory authority, Intuitive's Lanham Act claims¹¹ not only
23 require the Court to make rulings that might be duplicative or conflicting with potential FDA
24 rulings, but would also require the Court to step into the role of the role of a regulator that has

¹⁰ *POM Wonderful LLC v. Coca-Cola Co.* 573 U.S. 102, 115 (2014).

¹¹ In contrast to Intuitive's claims, SIS's Lanham Act claims are based on Intuitive falsely asserting that SIS can be in violation of FDA rules that have never been enforced or finalized.

1 spent years (indeed decades) considering the exact issue without ever issuing “final
 2 guidance.”¹²

3 This is not a situation where statutory and regulatory provisions are “clear in the relevant
 4 respects, and that clear statutory text is reinforced by the FDA’s . . . guidance.” *Azurity*
 5 *Pharm. v. Edge Pharma, LLC*, 45 F.4th 479, 501 (1st Cir. 2022). Rather, deciding in the first
 6 instance the standard for distinguishing “repair” from “remanufacturing” would “require a
 7 court to make a determination that ‘l[ies] at the heart of the task assigned the agency by
 8 Congress[.]’” *Id.* (quoting *Pejepscot Indus. Park, Inc. v. Me. Cen. R.R. Co.*, 215 F.3d 195,
 9 205 (1st Cir. 2000)). Simply put, there is “a lack of guidance from the FDA about an unclear
 10 statutory question, the resolution of which implicate[s] the FDA’s expertise[.]” *Azurity*
 11 *Pharm.*, 45 F.4th at 501 (discussing *Amarin Pharma, Inc. v. Int’l Trade Comm’n*, 923 F.3d
 12 959 (Fed. Cir. 2019)).

13 Although the line for allowable *Lanham Act* claims that can be resolved post-*POM* may
 14 not be entirely clear, Courts have repeatedly determined that this line is crossed where a ruling
 15 by the Court would “directly implicate the FDA’s rulemaking authority” or where “the law is
 16 unclear and the FDA’s particular expertise or rulemaking authority is required[.]” *World*
 17 *Nutrition Inc. v. Advanced Enzymes U.S.*, No. CV-19-00265-PHX-GMS, 2021 WL 632684,
 18 *3 (D. Ariz. Feb. 18, 2021) (quoting *Allergan USA Inc. v. Imprimis Pharm., Inc.*, No. SA
 19 CV 17-1551-DOC, 2017 WL 10526121, at *7 (C.D. Cal. Nov. 14, 2017) and *JHP Pharm.,*
 20 *LLC v. Hospira, Inc.*, 52 F. Supp. 3d 992, 1000 n.5, 1004 (C.D. Cal. 2014)).

21 ¹² The fact that Intuitive has found an expert willing to testify that [REDACTED]” (JVH Decl.
 22 Ex. 50 at ¶ 69) and base an entire opinion on that assumption is irrelevant where FDA itself
 23 clearly disagrees. *See* §§ III(D)-(E), *supra* (discussing years of workshops, white papers,
 24 comments, and draft guidance to “Clarify the Difference Between Servicing and
 25 Remanufacturing”); FDA Public Meeting, October 27, 2016 (JVH Decl. Ex. 43) at 17-18
 26 (FDA describing 1996 rulemaking to “cover third-party service organizations” and explaining
 27 that “this is where the refurbisher, reconditioner, servicers, all that verbiage comes from. . . .
 28 At that time no one could agree what the right term was. And I think we are still at that point
 where nobody really knows what the best term to use for this particular situation is.”); *Scott*,
 550 U.S. at 380 (explaining that a court may disregard the non-movant’s version of the facts
 on summary judgment where it is “blatantly contradicted by the record, so that no reasonable
 jury could believe it”). In sum, if the definition of remanufacturing has been clear since the
 1996, why would the OEM trade organizations have pushed legislation just last year entitled
 the “Clarifying Remanufacturing to Protect Patient Safety Act of 2022”?

1 As discussed in detail in Section III(D), despite years of public and private pressure from
 2 OEMs, FDA still has not made an original determination as to the standards that ISOs may
 3 use to determine whether their activities constitute remanufacturing. *See Belcher Pharm.,*
 4 *LLC v. Hospira, Inc.*, 1 F.4th 1374, 1380 (11th Cir. 2021) (approving of “cases recognizing
 5 that Lanham Act claims may be barred if their resolution requires an original determination
 6 that is committed to the FDA”); *cf. Rebotix Repair LLC v. Intuitive Surgical, Inc.*,¹³ 8:20-cv-
 7 2274-VMC-TGW, 2022 WL 3272538 at *6-7 (M.D. Fla. Aug. 10, 2022) (“For the reasons
 8 stated above, the Court will not at this juncture issue a determination with respect to whether
 9 or not Rebotix’s services and/or products require Section 510(k) clearance.”).

10 To the extent that the Court can rule on Intuitive’s FDA-related claims, SIS’s statements
 11 are not false or misleading. For example, SIS’s statement that “[t]he da Vinci® EndoWrist®
 12 is a ‘multi-use’ medical device [and] Multi-use devices, such as endoscopic instruments, have
 13 always been eligible for repair” was confirmed by FDA: “So the industry has not really had
 14 any involvement with FDA except our interactions with some of the trade associations since
 15 1998.” FDA Public Meeting, October 27, 2016 (JVH Decl., Ex. 43) at 20-21. SIS’s statement
 16 that “[t]he FDA does not regulate, nor certify, repairs [and instead] regulates third party
 17 reprocessing companies and single-use devices only” is consistent with FDA’s actual
 18 regulatory conduct, as well as its statutory authority.¹⁴ *Compare* § III(B), *supra*, (discussing
 19

20 ¹³ The District Court in *Rebotix* declined to grant summary judgment on Intuitive’s
 21 counterclaims because FDA might change its mind before trial. *Rebotix Repair*, 2022 WL
 22 3272538 at *6 (“If, however, the FDA has not issued an official, final determination on this
 23 issue on the eve of trial, the Court invites Rebotix to renew its motion for summary judgment
 24 as to these counterclaims.”). That decision, however, was based primarily upon Rebotix’s
 25 correspondence with FDA declining to issue an appealable decision. Although this
 26 correspondence further supports SIS’s motion, the key issue raised by the present motion is
 27 FDA’s failure to issue final guidance at the time of SIS’s purportedly false statements.

28 ¹⁴ To the extent that FDA may someday officially promulgate regulations and guidance
 29 that require 510(k) clearance for repair of hospital-owned multi-use devices such as that
 30 performed by SIS (including EndoWrists), it may run into substantial issues of whether it has
 31 statutory authority do so. *Compare West Virginia v. Environmental Protection Agency*, 142
 32 S.Ct. 2587, 2614 (2022) (“[W]e cannot ignore that the regulatory writ EPA newly uncovered
 33 conveniently enabled it to enact a program that, long after the dangers posed by greenhouse
 34 gas emissions “had become well known, Congress considered and rejected” multiple times.”)
 35 *with* § III(C), *supra* (discussing OEMs’ repeated failed attempts to pass statutes requiring
 36 510(k) clearance for “servicing” and “remanufacturing”) *and* § III(D), *supra* (FDA noting
 37 that it did not issue definitive regulations because “there was a lot of contentious discussions

1 statute authorizing FDA regulation of reprocessing of single-use devices) *with* § III(C), *supra*
 2 (OEMs repeatedly failing to pass legislation authorizing FDA to regulate “servicing” and
 3 “remanufacturing,” and Congress explicitly asking FDA to provide “a description of the
 4 statutory and regulatory authority” over servicing and remanufacturing and “whether
 5 additional authority is recommended”). SIS’s statements are also consistent with FDA’s
 6 actions on the specific issue of whether “[s]ome components/parts/materials have a defined
 7 intended use life which limits the life expectancy of the device . . . [and] [a]ctivities are
 8 performed to extend the device’s intended use life.” As discussed at § III(E), *supra*, FDA has
 9 not only declined to decide on final standards as to what constitutes remanufacturing, it also
 10 dropped all discussion of the specific issue of extension of intended use life from its draft
 11 guidance and capitulated to Rebotix when it requested a right to appeal to proper authorities
 12 within FDA.

13 Finally, for the same reasons that Intuitive cannot prevail on its FDA-related *Lanham Act*
 14 claims, SIS cannot possibly have engaged in unclean hands on these FDA issues. “To prevail
 15 on a defense for unclean hands in response to a Lanham Act claim, [a party] must show that
 16 [the other party’s] conduct . . . ‘was ‘inequitable’ or ‘unconscionable[.]’” *First Ascent Ventures*
 17 *Inc. v. DLC Dermacare LLC*, 312 Fed.Appx. 60, 61 (9th Cir. 2009); *see also Wheeler v. Am.*
 18 *Family Home Ins. Co.*, 20-cv-01502-JSW, 2022 WL 4624863 at *7 (N.D. Cal. Sep. 30, 2022)
 19 (“The doctrine of unclean hands requires unconscionable, bad faith, or inequitable conduct
 20 by the plaintiff in connection with the matter in controversy.”).

21 “Though the party against whom unclean hands is enforced need not have acted
 22 unlawfully, the court may only apply the doctrine where the party committed a ‘willful act
 23 concerning the cause of action which rightfully can be said to transgress equitable standards
 24 of conduct.’” *LL B Sheet 1, LLC v. Loskutoff*, 362 F. Supp. 3d 804, 821 (N.D. Cal. 2019)
 25 (quoting *Precision Instrument Mfg. Co. v. Auto. Maint. Mach. Co.*, 324 U.S. 806, 815 (1945)).
 26 In the present case, SIS cannot be said to have acted “willfully” when FDA doesn’t even
 27

28 about it . . . [a]nd it got to the point where this particular subject could have derailed the
 proposed rule from becoming final”).

1 know what standards it will enforce on remanufacturing and has twice punted on the specific
2 question of life extension of limited-use devices.

3 **VI. CONCLUSION**

4 For the foregoing reasons, SIS respectfully requests that the Court grant partial summary
5 judgment on Intuitive's counterclaims 1-4 and its unclean hands affirmative defense as they
6 relate to FDA.

7

8

9 Dated: March 23, 2023

MCCAULLEY LAW GROUP LLC

10

11

12

13

14

By: /s/ Joshua Van Hoven
JOSHUA V. VAN HOVEN

E-Mail: josh@mccauleylawgroup.com
3001 Bishop Dr., Suite 300
San Ramon, California 94583
Telephone: 925.302.5941

15

16

17

RICHARD T. MCCAULLEY (*pro hac vice*)
E-Mail: richard@mccauleylawgroup.com
180 N. Wabash Avenue, Suite 601
Chicago, Illinois 60601
Telephone: 312.330.8105

18

19

20

21

22

23

24

25

26

27

28

*Attorneys for SURGICAL INSTRUMENT
SERVICE COMPANY, INC.*